期刊文献+

个案全程管理模式在雌激素受体阳性乳腺癌病人中的应用研究 被引量:8

Application research of case management model to improve ER positive breast cancer patients
下载PDF
导出
摘要 目的:探讨分析个案全程管理模式在雌激素受体(ER)阳性乳腺癌病人中的应用效果。方法:将本中心确诊为ER阳性的乳腺癌病人200例依据实施个案管理前后分别作为对照组、观察组,调查分析病人的药物治疗的不良反应及满意度。结果:观察组病人的满意度较对照组高,实施前后比较差异有统计学意义。观察组病人的内分泌治疗药物不良反应率较对照组低,差异有统计学意义(P<0.05)。结论:在治疗ER阳性乳腺癌的过程中,采用个案全程管理模式显著提高了病人的满意度,值得临床推广应用。 Objective:To investigate and analyze the application effect of case management model to improve ER positive breast cancer patients. Methods:The center diagnosed as ER - positive breast cancer patients based on 200 cases before and after the implementation of case management as control group and obser- vation group, investigated and analyzed the patients' drug therapy adverse reactions and satisfaction. Results:The patients' satisfaction of observation group was higher than control group, there was significant difference between before and after the implementation. Endocrine treatment of adverse drug reaction rate of the patients in the observation group was lower than that in control group,the difference was statistically significant ( P 〈 0.05 ). Conclusion: In the treatment of ER positive breast cancer,using complete case management model significantly improved patient satisfaction ,it is worthy of clinical application.
出处 《护理实践与研究》 2013年第14期20-21,共2页 Nursing Practice and Research
基金 2012年深圳市科技计划项目(医疗卫生类)(201202052)
关键词 个案全程管理 雌激素受体 乳腺癌 满意度 Case management Estrogen receptor Breast cancer Satisfaction degree
  • 相关文献

参考文献8

二级参考文献85

  • 1<乳腺癌HER2检测指南>编写组,霍临明.乳腺癌HER2检测指南[J].中华病理学杂志,2006,35(10):631-633. 被引量:164
  • 2Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol, 2007, 25 : 118-145.
  • 3Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science, 1987, 235 : 177-182.
  • 4Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Eng J Med, 2001, 344:783- 792.
  • 5Marty M, Cognetti F, Maraninehi D, et al. Randomized phase Ⅱ trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol, 2005, 23: 4265 -4274.
  • 6Papaldo P, Fabi A, Ferretti G, et al. A phase Ⅱ study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease. Ann Oncol, 2006, 17: 630-636.
  • 7Kaufman B, Mackey JR, Clemens MR, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase Ⅲ TANDEM study. J Clin Oncol, 2009, 27:5529-5537.
  • 8von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol, 2009, 27: 1999- 2006.
  • 9Cameron D, Casey M, Press M, et al. A phase Ⅲ randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat, 2008, 112:533-543.
  • 10Romond EH, Perez EA, Bryant J, et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med, 2005, 353:1673-1684.

共引文献76

同被引文献61

引证文献8

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部